Revenue $93.53M, up 111.0% on a year earlier. Diluted EPS $0.16 against -$0.34.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $93.53M | $93.52M | $44.32M | +111.0% |
| Operating income | $10.10M | $7.98M | -$29.96M | |
| Net income | $8.06M | $5.21M | -$16.81M | |
| Diluted EPS | $0.16 | $0.10 | -$0.34 | |
| Operating cash flow | $19.69M | -$21.70M | -$27.25M | |
| Capital expenditures | -$494,000 | -$443,000 | -$1.79M | |
| Free cash flow | $19.20M | -$22.14M | -$29.04M |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| U.S. ICL Sales Growth | 7% | 4% | |
| EMEA ICL Sales Growth | -1% | 11% | |
| ICL Sales | $93.50M | $44.32M | +111.0% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Staar Surgical (STAA) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/STAA/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
